Company Monitoring Page for JNJ

latest headlines for company on cafepharma

Yumanity's end: J&J pays $26M for neuroscience assets as reverse merger erases biotech
Fierce Biotech
Mon, 06/6/22 - 10:29 am
Tags:
Yumanity Therapeutics, JNJ, Kineta, Merck, M&A
Janssen's Imbruvica Demonstrates Significant Survival Outcomes In Older Lymphoma Patients
BioSpace
Mon, 06/6/22 - 10:03 am
Tags:
ASCO 2022, JNJ, Janssen, Imbruvica, clinical trials, lymphoma
ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma
Pharmaforum
Mon, 06/6/22 - 09:52 am
Tags:
JNJ, Pfizer, ASCO 2022, bispecific antibodies, relapsed or refractory multiple myeloma
ASCO: J&J, AbbVie go back to Imbruvica's roots in lymphoma. Will lack of survival win matter?
Fierce Pharma
Fri, 06/3/22 - 10:27 am
Tags:
AbbVie, JNJ, ASCO 2022, FDA, Imbruvica, MCL
J&J, BMS arthritis drugs lowered death risk among COVID patients in federal study
Fierce Pharma
Thu, 06/2/22 - 07:29 pm
Tags:
JNJ, Bristol Myers Squibb, COVID-19, rheumatoid arthritis, clinical trials, Orencia, Remicade
Boston Scientific would be ‘good fit’ for increasingly acquisitive J&J, analysts say
Medtech Dive
Wed, 06/1/22 - 09:59 am
Tags:
JNJ, M&A, Boston Scientific, devices, Medtech
J&J takes Aurobindo to court over potential Erleada generic
Endpoints
Tue, 05/31/22 - 11:53 pm
Tags:
JNJ, Aurobindo, legal, generics, Erleada
ASCO: Is another pan-tumor drug on the horizon? Johnson & Johnson thinks Balversa could be it
Fierce Pharma
Fri, 05/27/22 - 10:19 am
Tags:
ASCO 2022, JNJ, Janssen, pan-tumor, Balversa
J&J's Momenta calls infringement against Viatris' Copaxone generic, but why now?
Fierce Pharma
Thu, 05/26/22 - 10:46 am
Tags:
JNJ, Momenta Pharmaceuticals, Viatris, Copaxone, generics, drug manufacturing
The patent winter is coming
EP Vantage
Wed, 05/25/22 - 10:41 am
Tags:
patents, biosimilars, patent cliff, Keytruda, Opdivo, Eliquis, Darzalex, Revlimid, Humira, Stelara, AbbVie, Merck, Bristol Myers Squibb, JNJ
In bankruptcy case, U.S. wants court to block J&J's use of high-powered, highly paid lawyer Neal Katyal
Fierce Biotech
Wed, 05/25/22 - 10:27 am
Tags:
JNJ, legal, bankruptcy
J&J's crown jewel Stelara faces another potential rival as biosim player Alvotech touts trial win
Fierce Pharma
Tue, 05/24/22 - 04:31 pm
Tags:
Alvotech, Teva Pharmaceutical, JNJ, Stelara, AVT04, biosimilars, psoriasis
Could This Biosimilar Drug Candidate Create a Blockbuster for Amgen?
Motley Fool
Mon, 05/23/22 - 06:44 pm
Tags:
Amgen, biosimilars, Stelara, JNJ
J&J's $230M blood pressure bet hits phase 3 endpoint, but questions linger about blockbuster potential
Fierce Biotech
Mon, 05/23/22 - 10:19 am
Tags:
JNJ, hypertension, Idorsia, clinical trials, aprocitentan
Janssen Presents New Data that could Set Anti-Inflammatory Drug Apart
BioSpace
Thu, 05/19/22 - 09:00 pm
Tags:
JNJ, Janssen, Tremfya, Skyrizi, AbbVie, anti-inflammatories
J&J MedTech Lands Clearance for INHANCE Shoulder System
Medical Devices and Diagnostics Industry
Thu, 05/19/22 - 10:47 am
Tags:
JNJ, DePuy Synthes, FDA, Inhance Shoulder System, Medtech, devices
J&J partner Aspen, with no orders for its COVID shot, warns low demand sends 'bad message'
Fierce Pharma
Wed, 05/18/22 - 10:49 am
Tags:
JNJ, Aspen Pharmacare, licensing, South Africa, vaccines, COVID-19
Big pharma’s biggest spenders revealed
EP Vantage
Tue, 05/17/22 - 10:29 am
Tags:
R&D, licensing, M&A, COVID-19, Big Pharma, Bristol Myers Squibb, JNJ, AbbVie, Sanofi, Merck, Novartis, Pfizer, AstraZeneca, Roche, GSK, Eli Lilly
J&J program adds Ena's infectious disease nasal spray to roster
Fierce Pharma
Mon, 05/16/22 - 07:41 pm
Tags:
JNJ, Ena Respiratory, nasal spray
UCB’s FDA setback delays competition in U.S. with blockbuster J&J psoriasis drug
MedCity News
Sun, 05/15/22 - 11:12 pm
Tags:
UCB Pharma, bimekizumab, psoriasis, FDA, JNJ

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.